Turn Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $367.4M
- Price
- $12.10
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.95%
- Volume
- 176.3K
About
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Quick stats
Shares outstanding30.4M
Computed float13.9M
Float / shares45.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002023016
AI Summary
AI-generated1/16
minorneutraloperations update
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Turn Therapeutics will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET, with CEO Bradley Burnam and Executive Clinical and Regulatory Lead Dr. Stephen M. Hahn delivering the presentation.
The presentation will detail the company's atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across patient subgroups such as those with lower EASI scores despite high investigator-assessed disease severity.
No new clinical or financial data accompanies the announcement; the lead candidate GX-03 remains in development for atopic dermatitis and onychomycosis. A live webcast and roughly six-month replay will be available on the company's investor relations site.